Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies, and its partner Zambon S.p.A., an international pharmaceutical company strongly committed to the CNS therapeutic area, announced today that the EU Committee for Medicinal Pro-ducts for Human Use (CHMP) recommended that the European Commission approve the use of Xadago™ (safinamide) as add-on to L-dopa alone or in combination with dopamine agonists, entacapone, amantadine, and/or anticholinergics, for the treatment of patients with mid-late stage Parkinson’s disease experiencing motor fluctuations despite being stabilized on ‘Standard of Care’.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7406951-chmp-xadago-parkinsons/
Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced the initiation of production of The PBA Film Project (working title), the first-ever documentary to provide an intimate look at real people living with a little-known neurologic condition called PseudoBulbar Affect (PBA). The award-winning filmmaker team of The PBA Film Project includes co-directors Doug Blush and Lisa Klein (Of Two Minds) and producer Julian Cautherley (The Crash Reel).
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7266955-avanir-pharmaceuticals-pseudobulbar-affect-pba-documentary/
ACG – the leading partner for pharmaceutical industry’s myriad requirements – is strengthening its product portfolio by launching several new machines at CPhI/P-MEC India, to be held during 2-4 December 2014, at Bombay Exhibition Centre, Mumbai.
P-MEC India, co-located with CPhI India, is one of the ‘must-attend’ events in the international pharmaceutical industry. With a booth that spreads over 1,000 sq. m., ACG will be displaying several new machines including the all-new ACG X.One Technology that reinvents the 12-bar safety features; Protab, a tablet press suited for small to medium batch sizes, and many more.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7391551-ACG-Launch-New-Machines-at-CPhI/
CPhI Worldwide, part of UBM Live’s Pharmaceutical Portfolio, today celebrates its 25th birthday by releasing the first in a series of ‘made at CPhI’ pharma stories. These will follow 25 pharma industry successes that have directly resulted from meetings at CPhI. The first story charts Global Pharmaceutical Relief from a first meeting at CPhI only two years ago to today and providing hundreds of millions of dollars worth of medicines to the developing world via NGOs- not just another business story, but a great example of the CPhI family helping to proliferate healthcare throughout the globe.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762554-cphi-worldwide-celebrates-25-years/
Jeffrey Bacha, president and CEO of DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) (“DelMar Pharma” or “DelMar”) discusses new clinical research and treatments in development for glioblastoma, the most common and severe form of brain cancer. Less than one out of three patients will survive two years after their diagnosis. DelMar is a cancer-focused company developing new therapies for patients with little to no treatment options.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7037951-delmar-pharmaceuticals-glioblastoma-brain-tumor-awareness-month
Raptor Pharmaceutical Corp. (“Raptor” or the “Company”) (Nasdaq: RPTP), today announced that the U.S. Food and Drug Administration (FDA) has approved PROCYSBI™ (cysteamine bitartrate) delayed release capsules for the treatment of nephropathic cystinosis in adults and children 6 years and older. In a Phase 3 study, PROCYSBI showed consistent cystine depletion over the full 12-hour dosing period. Sustained levels of cysteamine have not historically been achieved in the majority of patients in this population. Studies have shown that sustained cystine depletion in patients may significantly delay disease progression, including kidney dysfunction, dialysis, kidney transplant, organ failure and premature death.
To view Multimedia News Release, go to http://www.multivu.com/mnr/61338-raptor-pharmaceutical-procysbi-fda-approval-nephropathic-cystinosis
AbbVie (NYSE:ABBV) today marks its launch as an independent biopharmaceutical company, with employees from more than 40 countries and patients joining AbbVie leaders as they ring the first opening bell of 2013 at the New York Stock Exchange.
With a rich, 125-year heritage of developing pharmaceuticals, AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. A global enterprise that serves patients in more than 170 countries, AbbVie launches with an estimated $18 billion in annual revenues and a strong commitment to creating shareholder value through long-term growth potential and the continuation of the company’s history of shareholder dividends.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59757-abbvie-celebrates-launch-as-new-biopharmaceutical-company
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia’s Navy Yard Corporate Center. This milestone is part of the Company’s long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58559-iroko-pharmaceuticals-opens-philadelphia-headquarters-hq
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
Takeda today announced the launch of a new expert Report on COPD, introduced at a Takeda organised press conference on the occasion of the 2012 European Respiratory Society (ERS) Annual Congress taking place from 1- 5 September in Vienna, Austria.
The Report, entitled ‘The Shifting Paradigm in Chronic Obstructive Pulmonary Disease (COPD) Management,’ was initiated and developed by Takeda Pharmaceuticals International GmbH and is a compilation of opinion articles from a panel of key international respiratory experts, the European Federation of Allergy and Airways Diseases Patients’ Association (EFA) and COPD patients, reflecting updated guidance and research. The new expert Report was developed in response to a recent shift in emphasis in COPD management which now places future risk at equal importance to treatment of current disability. Treatment objectives are now divided into two groups: reducing symptoms and reducing risk.
To view Multimedia News Release, go to http://www.multivu.com/mnr/56582-expert-report-on-copd-launch
Boehringer Ingelheim Pharmaceuticals, Inc. and CancerCare® today announced the launch of My Cancer Circle™ (www.MyCancerCircle.net), a free, private, customizable online tool that enables caregivers of people facing cancer to organize and coordinate a circle of family members and friends to provide practical and emotional support. MyCancerCircle.net will provide caregivers of people facing cancer a simple, effective answer to a question they are asked constantly, “What can we do to help?”
To view Multimedia News Release, go to http://www.multivu.com/mnr/56339-boehringer-ingelheim-cancercare-my-cancer-circle-online-tool-caregivers
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
The data showed that treatment with SAR236553/REGN727 over 8 to 12 weeks significantly reduced mean low-density lipoprotein-cholesterol (LDL-C, or “bad” cholesterol) by 40% to 72% in patients with elevated LDL-C on stable dose of statins.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55299-sanofi-regeneron-pharmaceuticals-lipid-lowering-medications-pcsk9-antibody
